The Collaborative for CBD Science and Safety (CCSS; Washington, DC) is calling on industry, researchers, academia, healthcare practitioners, and regulators to accelerate research and the development of an appropriate federal regulatory framework for cannabidiol (CBD) and CBD-containing products. One year after the May 2019 U.S. Food and Drug Administration (FDA) public hearing on “Products Containing Cannabis or Cannabis-derived Compounds,” the public docket has been extended indefinitely, signaling that regulatory oversight and continued evaluation remain stymied by the lack of existing scientific data.“We must ensure consumers can trust the safety and quality of CBD-containing products and can rely on the product’s claims where appropriate,” said Sally Greenberg, executive director of the National Consumers League and CCSS Steering Committee Member, in a press release. “The importance of a separate regulatory pathway for CBD-containing products is underscored by the current spread of the coronavirus and the false, dangerous claims and misinformation about CBD that have accompanied the pandemic. In all cases, consumers remain at risk. FDA must continue to take action towards developing a regulatory pathway for CBD and begin mitigating threats posed by poor-quality products.”
